Afrezza denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for afrezza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Afrezza as Duplicate Therapy

Afrezza is an inhaled insulin product used for mealtime glycemic control in adults with diabetes. A duplicate-therapy denial from Humana typically arises when you are already prescribed one or more injectable insulin products — such as a rapid-acting or short-acting injectable insulin — and the plan's system flags Afrezza as therapeutically redundant because both products are classified as mealtime or prandial insulin. The plan's position is that you already have a covered way to address the same clinical function, making Afrezza unnecessary.

This framing overlooks the clinically meaningful differences between inhaled and injectable insulin: Afrezza has a distinct pharmacokinetic profile — it reaches peak activity and clears the body on a different timeline than most injectable rapid-acting insulins — and is delivered through a non-injection route. For some patients, this profile and delivery method are not interchangeable with injectable options. The clinical question is whether Afrezza provides a meaningfully different benefit for your specific situation that the injectable alternative does not adequately provide.

## Why This Denial Is Appealable

Duplicate-therapy determinations must reflect actual clinical interchangeability, not just formulary category similarity. If your prescribing physician has documented a specific clinical reason why Afrezza's pharmacokinetic profile or non-injection delivery is necessary or preferable for your care — and why your existing injectable insulin is not achieving the same result — then the two products are not clinically duplicative. The FDA-approved prescribing information for Afrezza describes its labeled indications and pharmacologic properties, which your physician can use to explain the clinical distinction.

## Federal Appeal Rights

• Internal Appeal: File a written appeal with Humana within the deadline on your denial notice. Include your physician's clinical rationale for Afrezza specifically.
• External Review (ACA §2719): If the internal appeal is denied, request external review by an IRO within approximately four months of the adverse benefit determination. IRO reviewers assess clinical interchangeability against accepted medical standards.
• Expedited Review: Available if delay in obtaining appropriate insulin coverage poses an urgent health risk.
• ERISA §503: Employer-plan members have the right to the full claim file and a full-and-fair review.

## Documentation to Gather

• Your diabetes diagnosis records, current insulin regimen, and glycemic monitoring data
• Documentation of your experience on your current injectable insulin: glycemic control achieved, any adverse effects, documented clinical limitations
• Your prescribing physician's letter explaining the specific clinical reason Afrezza was prescribed — including any relevant discussion of its pharmacokinetic profile or the significance of the non-injection delivery route for your care
• FDA-approved prescribing label for Afrezza (publicly available; your physician should reference it)
• Any relevant endocrinology specialist notes

## Criteria-Mapping Strategy

Your appeal must establish that Afrezza and your existing insulin are not clinically interchangeable in your specific situation.

| Humana Criterion | Your Documentation | |---|---| | Current insulin regimen documented | [Medication list, prescribing records] | | Clinical limitation of existing therapy | [Glycemic data, physician assessment] | | Distinct clinical need for Afrezza | [Prescriber letter explaining pharmacokinetic or delivery rationale] | | Physician recommendation supported | [Endocrinology or prescribing physician notes] |

A clear, specific prescriber letter explaining why the two products are not interchangeable for you is the cornerstone of this appeal.